Cellular based treatment modalities for unresectable hepatocellular carcinoma

doi:10.5306/wjco.v12.i5.290

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7985)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

560

WORD

186

HTML

4309

Figures (1-1)

322

Tables (1-3)

302

Sum=5679

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

311

Download

671

Sum=982

Publishing Process of This Article

Item

Count

Browse

435

Download

889

Sum=1324

May 24, 2021 (publication date) through Jan 13, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. May 24, 2021; 12(5): 290-308
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.290

Table 1 Ongoing clinical trials investigating chimeric antigen receptor-T cell therapy in the treatment of hepatocellular carcinoma according to ClinicalTrials.gov

Product	Phase	Estimated completion	Study/identifier
GPC3- CAR-T	I	November 2021	NCT04121273
CD147- CAR-T	I	May 2022	NCT03993743
GPC3- CAR-T	I	June 2022	NCT03980288
CAR-CLD18	N/A	December 2023	NCT03302403
GPC3- CAR-T	I	May 2024	NCT03884751
GPC3/TGF-CAR-T	I	August 2024	NCT03198546
GPC3- CAR-T	I	October 2036	NCT02905188

CAR: Chimeric antigen receptor; CD: Cluster of differentiation; GPC3: Glypican-3; TGF: Transforming growth factor.

Citation: Damiris K, Abbad H, Pyrsopoulos N. Cellular based treatment modalities for unresectable hepatocellular carcinoma. World J Clin Oncol 2021; 12(5): 290-308
URL: https://www.wjgnet.com/2218-4333/full/v12/i5/290.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i5.290